M P Economides1, P Mahale1, A Kyvernitakis1, F Turturro2, H Kantarjian3, A Naing4, J Hosry1, T L Shigle5, A Kaseb6, H A Torres1. 1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: Antiviral therapy improves hepatic outcomes in hepatitis C virus (HCV)-infected cancer patients. However, such patients are not treated simultaneously with antivirals and chemotherapy, owing to overlapping toxicities with previous standard of care treatment of pegylated interferon and ribavirin. AIM: To examine the safety and clinically-significant drug-drug interactions observed in patients who received simultaneous treatment with direct-acting antivirals (DAAs) and chemotherapy. METHODS: Safety was determined by the presence of adverse events which were graded according to the division of AIDS Table (version 2.0). Adverse events were monitored throughout antiviral treatment and up to 3 months after its completion. Drug-drug interactions were assessed using current online databases. Sustained virological response (SVR) was defined as absence of serum HCV RNA 12 weeks after end of DAA treatment. Cirrhosis was diagnosed via imaging, biopsy or with the use of non-invasive fibrosis markers. RESULTS: Twenty-one patients received concomitant treatment with DAAs and chemotherapy between January 2013 and September 2016. Concomitant treatment was started either for virological (14; 67%) or oncologic (7; 33%) reasons. DAAs used were sofosbuvir, ledipasvir, simeprevir, daclatasvir ± ribavirin. The adverse events observed were mainly constitutional (12; 57%), hematological and gastrointestinal (7; 33% each). Physicians changed the DAA regimens in two patients (10%) in anticipation of drug-drug interactions with daclatasvir and dexamethasone. The overall SVR rate was 95% (20/21). CONCLUSIONS: Hepatitis C virus-targeted antiviral therapy can be used concomitantly with selected anti-neoplastic agents under close monitoring for drug-drug interactions. This therapeutic intervention may prevent delay in the administration of chemotherapy in HCV-infected cancer patients.
BACKGROUND: Antiviral therapy improves hepatic outcomes in hepatitis C virus (HCV)-infected cancerpatients. However, such patients are not treated simultaneously with antivirals and chemotherapy, owing to overlapping toxicities with previous standard of care treatment of pegylated interferon and ribavirin. AIM: To examine the safety and clinically-significant drug-drug interactions observed in patients who received simultaneous treatment with direct-acting antivirals (DAAs) and chemotherapy. METHODS: Safety was determined by the presence of adverse events which were graded according to the division of AIDS Table (version 2.0). Adverse events were monitored throughout antiviral treatment and up to 3 months after its completion. Drug-drug interactions were assessed using current online databases. Sustained virological response (SVR) was defined as absence of serum HCV RNA 12 weeks after end of DAA treatment. Cirrhosis was diagnosed via imaging, biopsy or with the use of non-invasive fibrosis markers. RESULTS: Twenty-one patients received concomitant treatment with DAAs and chemotherapy between January 2013 and September 2016. Concomitant treatment was started either for virological (14; 67%) or oncologic (7; 33%) reasons. DAAs used were sofosbuvir, ledipasvir, simeprevir, daclatasvir ± ribavirin. The adverse events observed were mainly constitutional (12; 57%), hematological and gastrointestinal (7; 33% each). Physicians changed the DAA regimens in two patients (10%) in anticipation of drug-drug interactions with daclatasvir and dexamethasone. The overall SVR rate was 95% (20/21). CONCLUSIONS:Hepatitis C virus-targeted antiviral therapy can be used concomitantly with selected anti-neoplastic agents under close monitoring for drug-drug interactions. This therapeutic intervention may prevent delay in the administration of chemotherapy in HCV-infected cancerpatients.
Authors: Harrys A Torres; Pearlie P Chong; Marcos De Lima; Mark S Friedman; Sergio Giralt; Sarah P Hammond; Patrick J Kiel; Henry Masur; George B McDonald; John R Wingard; Maya Gambarin-Gelwan Journal: Biol Blood Marrow Transplant Date: 2015-08-06 Impact factor: 5.742
Authors: L Arcaini; D Vallisa; S Rattotti; V V Ferretti; A J M Ferreri; P Bernuzzi; M Merli; M Varettoni; A Chiappella; A Ambrosetti; A Tucci; C Rusconi; C Visco; M Spina; G Cabras; S Luminari; M Tucci; P Musto; M Ladetto; F Merli; C Stelitano; A d'Arco; L Rigacci; A Levis; D Rossi; P Spedini; S Mancuso; D Marino; R Bruno; L Baldini; A Pulsoni Journal: Ann Oncol Date: 2014-05-05 Impact factor: 32.976
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Christoph Höner Zu Siederdissen; Benjamin Maasoumy; Fiona Marra; Katja Deterding; Kerstin Port; Michael P Manns; Markus Cornberg; David Back; Heiner Wedemeyer Journal: Clin Infect Dis Date: 2015-11-26 Impact factor: 9.079
Authors: J Vermehren; K-H Peiffer; C Welsch; G Grammatikos; M-W Welker; N Weiler; S Zeuzem; T M Welzel; C Sarrazin Journal: Aliment Pharmacol Ther Date: 2016-08-23 Impact factor: 8.171
Authors: Michele Merli; Marco Frigeni; Laurent Alric; Carlo Visco; Caroline Besson; Lara Mannelli; Alice Di Rocco; Angela Ferrari; Lucia Farina; Mario Pirisi; Francesco Piazza; Véronique Loustaud-Ratti; Annalisa Arcari; Dario Marino; Antonello Sica; Maria Goldaniga; Chiara Rusconi; Massimo Gentile; Emanuele Cencini; Francesco Benanti; Maria Grazia Rumi; Virginia Valeria Ferretti; Paolo Grossi; Manuel Gotti; Roberta Sciarra; Maria Chiara Tisi; Isabel Cano; Valentina Zuccaro; Francesco Passamonti; Luca Arcaini Journal: Oncologist Date: 2018-12-14
Authors: Harrys A Torres; Jeff Hosry; Parag Mahale; Minas P Economides; Ying Jiang; Anna S Lok Journal: Hepatology Date: 2017-11-13 Impact factor: 17.425
Authors: Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet Journal: CA Cancer J Clin Date: 2017-07-06 Impact factor: 508.702
Authors: Julia L Marcus; Michael J Silverberg; Jennifer O Lam; Leo B Hurley; Jennifer B Lai; Varun Saxena; Suk Seo; Scott Chamberland; Charles P Quesenberry; Jamila H Champsi; Joanna Ready; Elizabeth Y Chiao Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: Hae Lim Lee; Si Hyun Bae; Bohyun Jang; Seawon Hwang; Hyun Yang; Hee Chul Nam; Pil Soo Sung; Sung Won Lee; Jeong Won Jang; Jong Young Choi; Nam Ik Han; Byung Joo Song; Jong Wook Lee; Seung Kew Yoon Journal: Gut Liver Date: 2017-11-15 Impact factor: 4.519